编号：2018-001 证券代码：300451 证券简称：创业软件 创业软件股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | | 中金公司、国泰君安证券、财通证券、申九资产、方正证 | | | | 券、兴业证券、国元证券、海通资管、太平洋证券（以上排 | | | 名不分先后） | | | 时间 | 2018 年 2 月 7 日 | | | 地点 | 创业智慧大厦 5 | 楼会议室 | | 上市公司接待人 | 董事会秘书、证券事务代表 | | | 员姓名 | | | | 投资者关系活动 | 告》披露情况进行了简 ...

编号：2020-001 证券代码：300451 证券简称：创业慧康 创业慧康科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300451 证券简称：创业软件 编号：2018-003 创业软件股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | | 弘悦资产、立溢投资、华安证券、国信证券、国泰君安、臻 | | | | 弘基金、鑫川资产、民生证券、招商证券、华泰柏瑞、海通 | | | | 新创、永望资产、中信建投、恒天财富、中农投资、银河证 | | | | 券、兴业证券、晟维资产、国泰元鑫、南京载德投资、北京 | | | | 方德正投、东兴证券、富舜资产、德晟福、观海资产、盈月 | | | | 投资、东方证券、光大证券等（以上排 ...

编号：2019-003 证券代码：300451 证券简称：创业慧康 创业慧康科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | MUFU | 、诺德基金、光大证券、海通证券、华泰柏瑞、上海 | | | | 小海豚投资、上海迈琪可、招商证券、山西证券、杭州钱 | | | | 投、博时基金、国泰君安、宇迪投资、华安自营、财通自 | | | | | | | | 营、申万宏源、莫尼塔研究、德邦证券、西南证券、禹合资 | | | 产等（以上排名不分先后） | | | 时间 | 2019 年 9 月 3 ...

编号：2019-004 证券代码：300451 证券简称：创业慧康 创业慧康科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 上海途灵、长城证券、相聚资本、长江证券、银河基金、民 | | | | 生证券、杭州银投资、人寿资产、圆信永丰基金、弘毅远方 | | | 基金（以上排名不分先后） | | | 时间 | 2019 年 11 月 15 | 日 | | | | | | 地点 | 现场会议 | | | 上市公司接待人 员姓名 | 董事会秘书 | | | | | 一、公司业务及非公开项目介绍 | ...

证券代码：300451 证券简称：创业软件 编号：2018-004 创业软件股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | | 中银基金、广发证券、星石投资、中邮基金、中金资管、东 北证券、人保资产（以上排名不分先后） | | | | | | 时间 地点 | 2018 年 4 月 26 日 创业智慧大厦 5 | 楼会议室 | | | | | | 上市公司接待人 员姓名 | 董事会秘书 ...

编号：2018-005 证券代码：300451 证券简称：创业软件 创业软件股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | █ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | | 广发证券、民生加银、海通证券、华创证券、博时基金、中 | | | 国太平（以上排名不分先后） | | | 时间 | 2018 年 10 月 31 日 | | | 地点 | 创业智慧大厦 5 | 楼会议室 | | 上市公司接待人 | 总经理：张吕峥先生 | | | 员姓名 | 董事会秘书：胡燕女士 | | | 投资者关系活动 | 一、公司整体情况介绍 | | | | 1、2018 ...

编号：2021-006 投资者关系活动 █特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 源乘投资、创金合信基金、泓澄投资、国泰君安、中庚基金致 君资产、Oasis Capital、申万宏源、中意资产、前润并投基金、 建信基金、华夏未来、中泰证券、晟盟资管、迎水投资、中信 资管、中信自营、煜德投资、兴业基金、国信弘盛、拾贝投资、 明河投资、金库资本、仁桥资产、上投摩根基金、鹏扬基金、 英睿投管、华夏基金、恩宝资管、安信证券、瑞颐投管、高投 产控、江苏瑞华、大正十方基金、天安人寿、安信基金、天虫 资本、中融人寿、中泰国际、东北证券、九泰基金、涌悦资产、 英大资产、汇泉投资、中天证券、稷定资本、和谐汇一资管、 上海青沣资管、财通基金、博时基金、万联自营、中金资管、 财通资管、中银基金、庶达资管、人保养老、东莞市榕果投管、 谦宏投资、中润投资、远策投资、光大保德信、景富投资、瑞 新资管、钰阳投资、泽铭投资、诺德基金、盛世景、华福证券 资管、东吴基金、长江资管、中国对外经济贸易信托有限公司、 太平基金、人保资产、南方睿 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥358,178,191.63, a decrease of 16.99% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥69,412,464.24, down 20.68% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥66,446,966.31, a decrease of 23.99% compared to the previous year[6]. - Total operating revenue for the third quarter was CNY 1,138,576,105.77, a decrease of 5.86% compared to CNY 1,209,502,704.67 in the same period last year[36]. - The net profit for the third quarter was 171,035,182.36, a decrease of 26% compared to 231,345,933.42 in the previous year[40]. - The total profit amounted to 187,710,734.04, down from 256,212,781.35, reflecting a decline of approximately 27%[40]. - Operating profit decreased to 184,043,324.72 from 256,603,951.33, indicating a drop of about 28%[40]. - Basic earnings per share were 0.11, down from 0.15, reflecting a decrease of about 27%[42]. - The company's total comprehensive income attributable to the parent company was 171,035,182.36, down from 231,345,933.42, indicating a decline of approximately 26%[41]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,848,385,891.48, an increase of 4.26% from the end of the previous year[6]. - Total assets reached CNY 5,848,385,891.48, compared to CNY 5,609,578,430.23 at the beginning of the year, indicating growth in asset base[32]. - Total liabilities increased to CNY 1,118,094,751.35 from CNY 1,010,278,633.60, reflecting higher financial obligations[35]. - The company's equity attributable to shareholders rose to CNY 4,697,242,940.25, compared to CNY 4,561,801,820.95, showing improved shareholder value[35]. Cash Flow - The company reported a net cash flow from operating activities of -¥178,849,931.62 for the year-to-date, reflecting a 28.16% increase in cash outflow compared to the previous year[6]. - The cash flow from operating activities showed a net outflow of -178,849,931.62, compared to -248,968,547.98 in the same period last year, representing an improvement[43]. - Cash inflow from operating activities totaled 937,387,271.90, up from 830,226,536.25, marking an increase of approximately 13%[43]. - The company reported a cash and cash equivalents balance of 1,254,807,152.95 at the end of the period, compared to 1,235,362,698.17 at the end of the previous year[46]. - Investment activities generated a net cash flow of 809,163,156.15, a significant decrease from 1,570,091,678.75 in the prior year[46]. - The company received cash from investment income totaling 14,209,859.56, an increase from 13,296,400.79 year-over-year[46]. Research and Development - The company’s R&D expenses increased by 55.95% year-on-year, indicating a significant investment in new product and technology development[10]. - Research and development expenses increased to CNY 149,697,194.79, up from CNY 136,146,832.70, reflecting a focus on innovation[36]. Shareholder Structure and Equity Incentives - The company reported a total of 206,690,519 restricted shares at the beginning of the period, with 1,826,565 shares released from restrictions during the quarter, resulting in 252,745,048 restricted shares at the end of the period[29]. - The company has 7,657,553 shares under the equity incentive plan, with 1,826,565 shares released from restrictions, leaving 5,830,988 shares still restricted[29]. - The company’s major shareholder, Ge Hang, had an initial restricted share count of 172,638,088, with 47,881,094 shares added to the restricted count, totaling 220,519,182 shares at the end of the period[23]. - The company’s top ten unrestricted shareholders include Philips (China) Investment Co., Ltd. with 155,003,087 shares, Zhejiang Xinsu Technology Co., Ltd. with 51,124,760 shares, and others totaling significant holdings[19]. - The company’s equity incentive plan allows for the release of restricted shares at a rate of 25% annually based on the previous year-end holdings for executives[23]. - The company’s total unrestricted shares held by the top ten shareholders account for a significant percentage of the total shares outstanding, indicating concentrated ownership[19]. - The company’s management has a structured plan for the release of restricted shares, ensuring alignment with long-term performance goals[23]. - The company is focused on maintaining a balance between incentivizing management and protecting shareholder interests through its equity incentive plan[29]. - The company’s financial strategy includes managing the release of restricted shares to optimize capital structure and shareholder value[29]. - The company’s performance metrics and shareholder structure are closely monitored to ensure compliance with regulatory requirements and to enhance investor confidence[19]. Operational Costs - Total operating costs amounted to CNY 898,731,935.85, down 5.02% from CNY 946,138,215.74 year-on-year[36]. - Cash and cash equivalents decreased to CNY 1,256,278,666.80 from CNY 1,619,154,719.36, indicating a reduction in liquidity[30]. - Accounts receivable rose to CNY 1,500,227,905.89, an increase of 19.92% from CNY 1,250,852,813.34[30]. - Inventory increased to CNY 268,136,499.11, up from CNY 240,505,018.58, suggesting potential challenges in sales or supply chain[30]. Strategic Focus - The company is focusing on market expansion and new product development as part of its strategic initiatives[34].

Business Focus and Strategy - The company reported a significant shift in its main business focus from product development and sales to system construction, service, and operation, including areas like smart healthcare and medical big data [10]. - The company aims to adjust its product development and market expansion strategies based on user demand and market competition to manage risks associated with innovative business expansion [10]. - The company is actively responding to national policy changes and macroeconomic conditions to maintain its market position and enhance its core competitiveness [25]. - The company is focused on continuous product innovation and market expansion to improve profitability amid uncertainties caused by the global pandemic [26]. - The company is enhancing its financial control measures to manage risks associated with resource limitations during its business expansion efforts [10]. Research and Development - The company plans to enhance R&D investment and strengthen collaboration with renowned universities and research institutions to mitigate technology and product development risks [6]. - The R&D department follows the CMMI5 software maturity development process, ensuring quality control and product testing throughout the development cycle [71]. - R&D investment for the first half of 2022 was 144.91 million yuan, an increase of 11.99% compared to the same period last year [77]. - The company has applied for 2 invention patents and 3 software copyrights during the reporting period, showcasing its commitment to innovation [86]. - The second-generation hardware device "Chuangye 5G Smart Gateway" has achieved mass production, enhancing the company's IoT solutions for healthcare institutions [86]. Financial Performance - The company's operating revenue for the first half of 2022 was ¥780,397,914.14, a slight increase of 0.31% compared to ¥778,007,750.65 in the same period last year [51]. - The net profit attributable to shareholders decreased by 28.77% to ¥101,516,847.62 from ¥142,513,537.57 year-on-year [51]. - The net profit after deducting non-recurring gains and losses was ¥107,502,433.08, down 7.50% from ¥116,217,305.76 in the previous year [51]. - The net cash flow from operating activities improved by 21.93%, reaching -¥189,123,434.61 compared to -¥242,234,432.39 in the same period last year [51]. - The basic earnings per share decreased by 22.22% to ¥0.07 from ¥0.09 in the previous year [51]. Market and Product Development - The company has established a comprehensive product system with over 300 self-developed products in the medical and health information technology sector [61]. - The "HuiKang Cloud 2.0" transformation strategy has been initiated, focusing on cloud-based solutions across various service scenarios including healthcare, insurance, and elderly care [61]. - The company is actively promoting the "Internet + Healthcare" model, with important products like the "Hybrid Cloud Internet Hospital Solution" and "Prescription Sharing Platform" [67]. - The company is focusing on the development of a smart healthcare ecosystem based on IoT technology, with products like the "Medical IoT Access Platform" and "Digital Ward" [68]. - The company employs a dual-layer sales system, combining product division sales with regional marketing centers to enhance market reach [70]. Operational Challenges and Risks - The company anticipates seasonal fluctuations in its operations, with project acceptance and payment concentrated in the second half of the year, particularly in Q4 [16]. - The company faces potential goodwill impairment risks from acquisitions and will implement comprehensive post-merger management to ensure the competitiveness of acquired entities [20]. - The company is committed to talent retention strategies, including establishing a postdoctoral workstation and implementing employee stock ownership plans to prevent core talent loss [19]. - The company emphasizes the importance of maintaining effective communication with clients to mitigate the impacts of the pandemic on operations and project development [26]. Shareholder and Equity Information - The company’s stock incentive plan included the unlocking of 623,171.2 shares, representing 0.40% of the total share capital [135]. - The total number of ordinary shareholders at the end of the reporting period was 37,057 [185]. - The total number of restricted shares at the beginning of the period was 212,606,331, with 6,231,712 shares released during the period [184]. - The number of shares held by the top shareholder, Ge Hang, is 220,519,182, representing 14.23% of total shares [185]. - The company did not distribute cash dividends or bonus shares for the half-year period, nor did it increase capital through reserves [134]. Investment and Fundraising - The total investment amount for the reporting period was 121,617,009.81, an increase of 254.76% compared to the previous period [105]. - The company raised a total of RMB 131,760.96 million through a private placement of 79,806,759 shares at RMB 16.51 per share, with a net amount of RMB 128,877.04 million after deducting fees [108]. - The total amount of raised funds invested during the reporting period was RMB 9,158.15 million, with a cumulative investment of RMB 83,716.43 million [109]. - The "Data Integration Driven" project has an investment commitment of RMB 68,502.34 million, with 61.54% of the investment completed by the end of the reporting period [110]. - The "Marketing Service System Expansion" project has an investment commitment of RMB 10,023.56 million, with 55.43% of the investment completed [113]. Corporate Governance and Compliance - The company has not engaged in any derivative investments during the reporting period [119]. - The company has not sold any significant assets during the reporting period [121]. - The company has not engaged in any entrusted loans during the reporting period [120]. - The company has maintained a clean record with no non-operating fund occupation by major shareholders or related parties [148]. - The company has not faced any administrative penalties related to environmental issues during the reporting period [142].